Staff Spotlight: Michael Holter, PhD
Job Title: Postdoctoral Fellow
Hometown: Centennial, CO
What made you want to work for the Ivy Brain Tumor Center?
The innovative structure of the Ivy Brain Tumor Center is a fantastic opportunity for a researcher to make an impact in the life of a patient. This is an extremely rare possibility that is impossible to pass up!
What does it mean to you to work for the Ivy Center?
It is an incredible feeling to be at the forefront of novel therapeutic approaches for glioblastoma patients through the innovative Phase 0 trials. I’m happy to contribute to a fantastic team on a daily basis to help patients in their battle against GBM.
What motivated you to get into the medical field, specifically research?
I’ve always had a natural curiosity for cell biology and ultimately, how the brain works. I wanted to explore this further through basic science research and through my studies decided to connect my love for neuroscience with therapeutic avenues. The Ivy Brain Tumor Center provides a great environment to pursue both of these interests.
What’s the culture like at the Ivy Center? What makes working here different from other research centers?
The Ivy Center has put together a fantastic team of scientists that foster excellent communication. Everyone here works together really well and we have a team mentality that allows us to work toward our collective common goal of helping patients.
What is it like to know that you’re playing an integral role in identifying new therapies that will contribute to a cure for brain cancer?
Knowing that the discoveries we make in the lab can translate to a patient in a short timespan is an exhilarating feeling. Brain cancer is such a destructive disease not only for the patient, but also for the families. The chance to alleviate these pains makes me feel really good about what I do.
What keeps you motivated when dealing with such a complex disease?
The complexity of this disease keeps us motivated to continue doing what we do. The more that we learn, the more we are able to expand our knowledge about glioblastoma and the drugs that might be effective on both a mechanistic and therapeutic level. The opportunities here are tremendous and we are ideally positioned to help many people affected by this disease and change the status quo.